Article Versions Notes

Feng J, Li S, Zhang B, Duan N, Zhou R, Yan S, Elango J, Liu N, Wu W. FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells. Marine Drugs. 2022; 20(1):76. https://doi.org/10.3390/md20010076

Feng, Jingwen, Songlin Li, Bing Zhang, Namin Duan, Rui Zhou, Shike Yan, Jeevithan Elango, Ning Liu, and Wenhui Wu. 2022. "FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells" Marine Drugs 20, no. 1: 76. https://doi.org/10.3390/md20010076

Feng, J., Li, S., Zhang, B., Duan, N., Zhou, R., Yan, S., Elango, J., Liu, N., & Wu, W. (2022). FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells. Marine Drugs, 20(1), 76. https://doi.org/10.3390/md20010076